Solid Tumor Malignancy
Conditions
Keywords
solid tumor, Radionuclide Drug Conjugates, Companion Diagnostics, FAP
Brief summary
Stage 1 (Safety study for 68Ga-NRT6020 Injection): The goal of this clinical trial stage is to evaluate the safety of 68Ga-NRT6020 Injection in participants with advanced solid tumors. The study will also assess the biodistribution, radiation dosimetry, imaging profile, and pharmacokinetics of the drug. Additionally, researchers aim to investigate how consistent the PET/CT imaging results of 68Ga-NRT6020 are with 18F-FDG PET/CT imaging and FAP immunohistochemistry (IHC) results. Stage 2 (Safety and tolerability study for 177Lu-NRT6020 Injection): This stage focuses on evaluating the safety and tolerability of 177Lu-NRT6020 Injection in FAP-positive participants with advanced solid tumors. Researchers will also assess the safety of 68Ga-NRT6020 Injection in this population. The study will evaluate the biodistribution, radiation dosimetry, pharmacokinetics, and preliminary efficacy of 177Lu-NRT6020 Injection. Additionally, the imaging profile of 68Ga-NRT6020 and its consistency with other imaging techniques will be further investigated. Stage 3 (Preliminary efficacy study for 68Ga/177Lu-NRT6020 Injection): The objective of this stage is to evaluate the safety of 177Lu-NRT6020 Injection and 68Ga-NRT6020 Injection in FAP-positive participants with advanced solid tumors, as well as to determine the recommended phase 2 dose (RP2D) of 177Lu-NRT6020 Injection. The study will also assess the preliminary efficacy, biodistribution, radiation dosimetry, and pharmacokinetics of the drugs. Furthermore, researchers will investigate the imaging profile of 68Ga-NRT6020 and its consistency with other imaging techniques.
Detailed description
During the study, 68Ga-NRT6020 served as the companion diagnostic agent for 177Lu-NRT6020 to select eligible patients. This stage 2 and stage 3 of the study is designed as a multi-center, multiple-dose, parallel-cohort study, and will enroll FAP-positive (FAP-positive is defined by positive PET/CT imaging results for 68Ga-NRT6020; and dose of 68Ga-NRT6020 will be confirmed by the SRC after stage 1) patients with advanced solid tumors who have failed or have no available standard therapy.
Interventions
DIAGNOSTIC_TEST68Ga-NRT6020 Injection
Participants will receive a single intravenous injection of 68Ga-NRT6020 Injection (3 mCi or 5 mCi) and PET/CT scans at multiple time points.
DRUG177Lu-NRT6020 Injection (stage 2)
It is planned to evaluate 4 dose levels of 177Lu-NRT6020 Injection: 50mCi, 100mCi, 150mCi and one/more adaptive dose groups (ranged from 150 to 250 mCi, the specific doses and/or doses with other frequencies within the range of 150\~250mCi, need to be determined after the completion of the dose-limiting toxicity (DLT) assessment for the previous three dose groups, in combination with the safety, pharmacokinetics and radiation dosimetry results of the participants, following confirmation by the SRC) which will be administered every 6 weeks (Q6W), and/or other dosing intervals determined by the SRC, for up to 6 cycles.
DRUG177Lu-NRT6020 Injection (stage 3)
Participants will receive intravenous injection of 177Lu-NRT6020 Injection, administered Q6W and/or other dosing intervals determined by the SRC, for up to 6 cycles.
Sponsors
Chengdu New Radiomedicine Technology Co. LTD.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: 1. Male or female participants aged 18-80; 2. Histologically or cytologically confirmed advanced solid tumors; advanced solid tumors patients who have failed prior standard therapies or deemed unsuitable for standard therapies (only for stage 2 and stage 3); 3. Have at least one measurable lesion as per RECIST v1.1/PERCIST criteria; 4. For stage 2 and stage 3, a positive 68Ga-NRT6020 Injection PET/CT imaging results is required; 5. Participants must have adequate organ function; 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 7. Life expectancy ≥3 months; 8. For women of childbearing potential, a negative blood pregnancy test within 3 days before the first dose is required, and fertile male and female participants of childbearing potential must agree to use effective contraception with their partners from the signing of the informed consent form until 12 months after the last dose of the investigational drug. Key
Exclusion criteria
1. Known allergy to 68Ga-NRT6020 Injection, 177Lu-NRT6020 Injection, or any of their ingredients, such as alcohol; 2. Presence or suspicion of primary central nervous system tumors or intracranial metastasis; 3. For stage 1: Received prior antitumor treatments within 7 days before the investigational drug dosing, and/or plan to receive antitumor treatments during the safety observation period; For stage 2 and stage 3: Received prior antitumor treatments within 4 weeks before the initial investigational drug dosing, including chemotherapy, radiotherapy, biological therapy, endocrine therapy, targeted therapy, immunotherapy, etc.; 4. History of other malignancies within 5 years prior to the first dose of the investigational drug, excluding cured non-melanoma skin cancer, early-stage papillary thyroid cancer, and cervical carcinoma in situ; 5. Presence of severe or uncontrolled cardiac diseases requiring treatment; 6. High risk of bleeding; 7. Active syphilis or human immunodeficiency virus (HIV) antibody positive; 8. HBsAg-positive or HBcAb-positive with HBV-DNA levels above the detection limit; 9. Failure to alleviate previous antitumor treatment toxicities to Grade 0 or 1 according to CTCAE v5.0; 10. Participate in any other clinical trials within 1 month before the first dosing of 68Ga-NRT6020 Injection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | Through study completion, an average of 1 year | Occurrence of adverse events |
| Dose-limiting toxicity (DLT) (stage 2) | After the first dose of 177Lu-NRT6020 administration, up to 42 days | Evaluate the safety and tolerability of 177Lu-NRT6020 |
| Maximum tolerated dose (MTD) (if any) or recommended dose for expansion study of 177Lu-NRT6020 Injection (stage 2) | Through study completion, an average of 1 year | Evaluating the safety and tolerability of 177Lu-NRT6020 with the aim of determining the optimal dose |
| RP2D for 177Lu-NRT6020 Injection (stage 3) | Through study completion, an average of 1 year | Determine the optimal dose of 177Lu-NRT6020 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Standardized uptake values (SUV) (stage 1) | After the administration of 68Ga-NRT6020, within 24 hours | Evaluate the distribution of 68Ga-NRT6020 Injection in various tissues and organs of the human body |
| Absorbed dose (stage 1) | After the administration of 68Ga-NRT6020, within 24 hours | Evaluate the dosimetry characteristics of 68Ga-NRT6020 Injection in various tissues and organs of the human body |
| Effective dose (stage 1) | After the administration of 68Ga-NRT6020, within 24 hours | Evaluate the dosimetry characteristics of 68Ga-NRT6020 Injection in the human body |
| Scanning time window (stage 1) | After the administration of 68Ga-NRT6020, within 3 hours | Compare the imaging parameter in different timepoints and different doses |
| Radioactivity in biological specimen (stage 1) | After the administration of 68Ga-NRT6020, within 24 hours | Detect the radioactivity in specimen samples at various time points |
| Peak Plasma Concentration (Cmax) of 68Ga-NRT6020 (stage 1) | After the administration of 68Ga-NRT6020, within 24 hours | Multiple blood samples will be collected to determine the pharmacokinetic profiles of 68Ga-NRT6020 Injection |
| Time to reach maximum concentration (Tmax) of 68Ga-NRT6020 (stage 1) | After the administration of 68Ga-NRT6020, within 24 hours | Multiple blood samples will be collected to determine the pharmacokinetic profiles of 68Ga-NRT6020 Injection |
| Area under the plasma concentration versus time curve (AUC) of 68Ga-NRT6020 Injection (stage 1) | After the administration of 68Ga-NRT6020, within 24 hours | Multiple blood samples will be collected to determine the pharmacokinetic profiles of 68Ga-NRT6020 Injection |
| Half life (t1/2) of 68Ga-NRT6020 (stage 1) | After the administration of 68Ga-NRT6020, within 24 hours | Multiple blood samples will be collected to determine the pharmacokinetic profiles of 68Ga-NRT6020 Injection |
| Standardized uptake values (SUV) (stage 2 and stage 3) | After the administration of 177Lu-NRT6020, at least 7 days | Evaluate the distribution of 177Lu-NRT6020 Injection in various tissues and organs of the human body |
| Absorbed dose (stage 2 and stage 3) | After the administration of 177Lu-NRT6020, at least 7 days | Evaluate the dosimetry characteristics of 177Lu-NRT6020 Injection in various tissues and organs of the human body |
| Effective dose (stage 2 and stage 3) | After the administration of 177Lu-NRT6020, at least 7 days | Evaluate the dosimetry characteristics of 177Lu-NRT6020 Injection in the human body |
| Objective response rate (ORR) (stage 2 and stage 3) | After the administration of 177Lu-NRT6020, within 1 year | Evaluated by the investigator in accordance with the RECIST v1.1/PERCIST criteria |
| Duration of response (DOR) (stage 2 and stage 3) | After the administration of 177Lu-NRT6020, within 1 year | Evaluated by the investigator in accordance with the RECIST v1.1/PERCIST criteria |
| Progression-free survival (PFS) (stage 2 and stage 3) | After the administration of 177Lu-NRT6020, within 1 year | Evaluated by the investigator in accordance with the RECIST v1.1/PERCIST criteria |
| Radioactivity in biological specimen (stage 2) | After the administration of 177Lu-NRT6020, at least 7 days | Detect the radioactivity in specimen samples at various time points |
| Peak Plasma Concentration (Cmax) of 177Lu-NRT6020 (stage 2 and stage 3) | After the administration of 177Lu-NRT6020, at least 7 days | Multiple blood samples will be collected to determine the pharmacokinetic profiles of 68Ga-NRT6020 Injection |
| Time to reach maximum concentration (Tmax) of 177Lu-NRT6020 (stage 2 and stage 3) | After the administration of 177Lu-NRT6020, at least 7 days | Multiple blood samples will be collected to determine the pharmacokinetic profiles of 68Ga-NRT6020 Injection |
| Area under the plasma concentration versus time curve (AUC) of 177Lu-NRT6020 (stage 2 and stage 3) | After the administration of 177Lu-NRT6020, at least 7 days | Multiple blood samples will be collected to determine the pharmacokinetic profiles of 68Ga-NRT6020 Injection |
| Half life (t1/2) of 177Lu-NRT6020 (stage 2 and stage 3) | After the administration of 177Lu-NRT6020, at least 7 days | Multiple blood samples will be collected to determine the pharmacokinetic profiles of 68Ga-NRT6020 Injection |
| Objective response rate (ORR) (stage 3) | After the administration of 177Lu-NRT6020, within 1 year | Evaluated by the Independent Review Committee (IRC) in accordance with the RECIST v1.1/PERCIST criteria |
| Duration of response (DOR) (stage 3) | After the administration of 177Lu-NRT6020, within 1 year | Evaluated by the Independent Review Committee (IRC) in accordance with the RECIST v1.1/PERCIST criteria |
| Progression-free survival (PFS) (stage 3) | After the administration of 177Lu-NRT6020, within 1 year | Evaluated by the Independent Review Committee (IRC) in accordance with the RECIST v1.1/PERCIST criteria |
Countries
China
Contacts
CONTACTXinxing Zhang
Outcome results
None listed